Methods: The lipid-lowering effects of T3 were investigated using HepG2 liver cell line, hypercholesterolemic mice and borderline-high cholesterol patients.
Introduction
In 1922, embryologist Evans discovered tocopherols (TP), which are needed for human reproduction 1, 2) . More than 40 years later, isolation of tocotrienol (T3) from latex was first reported by Morton 3) . To date, vitamin E has been found to consist of T3 possess anti-cholesterol 6) and anti-cancer activities 7) . Cholesterol and triglycerides are two forms of lipid. Both cholesterol and triglycerides are necessary for life because cholesterol is required for building cell membranes and making several essential hormones 8) whereas triglycerides provide much of the energy needed for cells to function 9) . Physiologically, they can not dissolve and circulate in the blood without combining with lipoproteins (VLDL, LDL, HDL and chylomicrons). Apart from chylomicrons, which transport primarily triglycerides from the exogenous pathway (intestinal absorption), LDL/HDL and VLDL are the major lipoproteins responsible for carrying cholesterol and triglycerides from the endogenous pathway (hepatic biosynthesis) respectively 10) . In the past three decades, the lipid-lowering properties of T3 have been demonstrated in cell lines 6) , animal models 11) and humans 12) , focusing primarily on the reduction of hepatic cholesterol biosynthesis. The in vitro mechanism may involve a reduced 3-hydroxy-3-methyl-glutar yl-CoA reductase (HMGCR) protein synthesis rate and an increased degradation rate, as found in hepatoma HepG2 cells 13) . The different T3 isomers possess various degrees of cholesterol-lowering activity.
T3 is claimed to be more active than T3 in inhibiting HMGCR, whereas T3 has a slight effect 14) . In contrast, TP induces HMGCR activity 15) . Clinical findings concerning the effects of T3 on circulating cholesterol, triglycerides and lipoproteins in humans are inconsistent. The four earlier studies published by Tan et al. 16) and Qureshi et al. 12, 17) showed lipid-lowering effects (total cholesterol, LDL and triglyceride reduction) of the T3-rich fraction (TRF) from palm oil. In these studies, no changes were found in serum HDL cholesterol concentration. In contrast to the positive studies, several research groups failed to observe significant changes in the serum lipid and lipoprotein profiles after supplementation with TRF. In the study by Wahlqvist 18) , hypercholesterolemic patients who used supplements containing TRF in increasing doses from 60 − 240 mg/day for 20 weeks did not show an improved lipid profile. These findings were confirmed by Tomeo 4) , who examined the TRF effects in increasing doses from 224 − 336 mg/day for 18 months on serum lipids and lipoproteins in hyperlipidemic men and women with carotid atherosclerosis. Furthermore, Mensink 19) detected no changes in serum lipid and lipoprotein concentrations in mildly hypercholesterolemic men who received supplements containing TRF consisting of 135 mg/day of T3 for 6 weeks. O'Byrne 20) supplemented hypercholesterolemic patients with 250 mg/ day of , , or -tocotrienyl acetates from palm oil for 8 weeks in addition to an AHA step diet. Serum lipid and lipoproteins were also unaffected.
Given the controversial findings from previous in vitro, in vivo and human studies, we aimed to evaluate the lipid-lowering effects of T3 in the liver cell line HepG2, and hypercholesterolemic mice and patients. In addition, this study aimed to investigate whether high TP (50%) co-supplementation with T3 will be less effective than purified T3 supplementation. Finally, a 8-week hypercholeterolemic human trial with 120 mg/day T3 supplementation was conducted in Japan to evaluate the impact of the two most potent T3 isomers on serum cholesterol, triglycerides, LDLcholesterol, and HDL-cholesterol. Since LDL particles vary in size/density, and studies have shown that smalldense LDL (sd-LDL) particles equate to a higher risk factor for coronary heart disease than larger and less dense LDL particles 21) , we further evaluated whether T3 supplementation impacted the 20 fractions of triglycerides and cholesterol lipoproteins of various size/density 22) .
Materials and Methods

Cell Line, Culture Conditions and Chemicals
Human hepatocellular carcinoma cells (HepG2) (ATCC, Rockville, MD) were maintained in RPMI 1640 with L-glutamine and 25 mM HEPES (E15-842; PAA Laboratories GmbH, Austria) supplemented with 10% fetal bovine serum (FBS) and 1% penicillin streptomycin at 37 in 5% CO2. HepG2 cells were prepared for treatment (day 0) in 10% FBS-supplemented media. On day 1, the cells were pre-treated in media which had the FBS replaced with 10% lipoprotein-depleted serum (LPDS) (BioWest, France), and supplemented with 50 M mevastatin (Sigma Aldrich, St Louis, MO) plus 50 M mevalonic acid lactone (Sigma Aldrich). After 16h, the cells were treated with 5 M 25-hydroxycholesterol (25-HC) (Sigma Aldrich), 5 M simvastatin (ST) (Sigma Aldrich), 20 M -, T3 (Davos Life Science, Singapore), and 20 M T3 (Davos Life Science) prepared in fresh media containing 50 M mevastatin and 10 M mevalonic acid lactone (Sigma Aldrich). Cells were harvested after 16 h for analyses. T3 and TP isomers were purified from palm oil using Davos separation technology. Crude palm oil feed was purchased from KLK Berhad. Using the corresponding VE isomers as a reference standard, the purity was verified as ≥ 97% by the HPLC percentage area. Dimethyl sulfoxide (DMSO) was purchased from Sigma Aldrich.
Cell Viability Study
For cell viability study, 5 10 3 HepG2 cells resuspended in 100 L medium were plated in each well of a 96-well plate. The cells were then treated with different concentrations (20, 40 , 80 M) of T3 isomers for 24 h. After treatment, 20 L MTT solution was added to each well and the cells were incubated at 37 for 2 h. Formazan crystals were then re-suspended in 100 L DMSO and the intensity at 595 nm was measured. Each experiment was repeated three times in triplicate and the growth curves showed the means and standard deviations.
T3 Extraction from Serum
Sera were thawed and sonicated in an ultrasonic bath (Lab Companion, Vernon Hills, IL) for 5 min, followed by vortexing for 10 sec. Then, 100 L serum was transferred into an IWAKI Pyrex glass tube (Jawa Tengah, Indonesia) containing 900 L water, and 5 L T3 of 99% purity (100 mg T3 dissolved in 1 mL ethanol) was used as an internal standard solution and added to the mixture. The tube was vortexed for 10sec and sonicated for 2 min. A 4 mL sample of butylated hydroxytoluene (BHT; Sigma Aldrich) solution (5 mg BHT in 100 mL heptane) was added to the tube to minimize the oxidation of target analytes. Liquid-liquid extraction was performed by vortexing vigorously for 10 sec. After liquid-liquid extraction, the tubes were centrifuged at 3450 xg for 5 min in Heraeus Multifuge 3-SR Centrifuge (Newport Pagnell, Buckinghamshire). A 3.9 mL sample of the organic layer was transferred into another Pyrex tube. The extraction was repeated and the second organic layer was removed and pooled with the first layer. The organic solution was evaporated using a Buchi rotavapor R-205 (Flawil, Switzerland), and the dried residue was reconstituted in 1.5 mL heptane and filtered, followed by HPLC analysis
Western Blotting
Cell lysates were prepared by suspending cell pellets in lysis buffer [50 mM Tris-HCl (pH8.0), 150 mM sodium chloride, 1% NP-40, 0.5% deoxycholate, 0.1% SDS, 1 mg/mL aprotinin, 1 g/mL leupeptin and 1 mM phenylmethylsulfonyl fluoride]. Protein concentration was measured using the DC Protein Assay kit (Bio-Rad, Hercules, CA). An equal amount of protein (30 g ) was loaded onto a 10% SDS polyacrylamide gel for electrophoresis and then transferred onto a polyvinylidene difluoride (PVDF) membrane (Amersham, Piscataway, NJ). The membrane was then probed against HMGCR (H-300) (Santa Cruz Biotechnology, Santa Cruz CA), sterol regulatory element binding proteins 1/2 (SREBP-1/2) (BD Biosciences, Pharmingen, USA), LDL receptor (LDLr) (EP1553Y) (Novus Biologicals, CO), and PPAR (H-98), APO100 and diacylglycerol O-acyltransferase 2 (DGAT2) (H70) (Santa Cruz Biotechnology). The expression of -actin (I-19) (Santa Cruz Biotechnology) was assessed as a loading control for total cell lysates. After incubation with HRP-conjugated secondary antibodies (Santa Cruz Biotechnology), signals were detected by the ECL Wstern blotting system (Perkin Elmer, Waltham, MA).
Real-Time Polymerase Chain Reaction
Total RNA was isolated from the treated cells using the Promega SV Total RNA Isolation system (Promega, USA). The cDNA was synthesized from 1 g total RNA using the Promega ImProm-Reverse Transcription System (Promega). Real-time PCR was carried out using the ABI PRISM ® Sequence Detection System (Applied Biosystems, USA) according to the manufacturer's protocol for TaqMan ® Gene Expression Assays (Applied Biosystems). A standardized amount of 100 ng cDNA was used per PCR reaction. The PCR procedure was performed with specific TaqMan ® Probe sequences (HMGCR: 5'to3' TGGTA CCATG TCAGG GGTAC GTCAG; GAPDH: 5'to3' GGCGC CTGGT CACCA GGGCT GCTTT) linked to a reporter dye, 6-FAM, at the 5' end. Cycle parameters on the 7900HT Sequence Detection System were according to the recommended standard thermal cycler protocol: 40 cycles of 95 for 15 sec and 60 for 1 min. Each PCR reaction was performed at least in duplicate and the level of each gene expression was determined relative to the normalized GAPDH gene.
Reverse Transcription Polymerase Chain Reaction (RT-PCR)
The same source of synthesized cDNA was used for RT-PCR. A standardized amount of 100 ng cDNA was used per PCR reaction. The PCR procedure was performed with specific human primer pair sequences (GAPDH: 5'to3'F ATGAC ATCAA GAAGG TGGTG; 5'to3'R CATAC CAGGA AATGA GCTTG; SREBP1: 5'to3'F TGCTG ACCGA CATCG AAGAC; 5'to3'R CTGTC TTGGT TGTTG ATAAG CTGAA; SREBP2: 5'to3'F GGCGA TGGAC GACAG CGGCG GCT; 5'to3'R GTCAG TCTGG CTCAT CTTTG ACCTT; Apo B48: 5'to3' F CTGCA AATGA GACAC TTTCT C; 5'to3'R TGCTC TCATC AAAGG CATGA; Apo B100: 5' to3'F GCAAG GAGCA ACACC TCTTC; 5'to3'R TAATA CGACT CACTA TAGGG AGGTC CACAC TGAAC CAAGG TC; Apo C3: 5'to3'F ATGCA CTGAG CAGCG; 5'to3'R ACGGC TGAAG TTGGT; Apo E: 5'to3'F ACCCA GGAAC TGAGG GC; 5'to3'R CTCCT TGGAC AGCCG TG; DGAT2: 5'to3'F AGTGG CAATG CTATC ATCAT CGT; 5'to3'R AAGGA ATAAG TGGGA ACCAG ATCA). Cycle parameters were as follows: 95 for 10 min, 40 cycles of 94 for 30 sec, 60 for 1 min and 72 for 2 min, and 72 for 10 min. GAPDH expression was assessed as the loading control.
In vivo Hypercholesterolemic Mice
The experimental protocol was approved by the IACUC committee of the A-STAR Biological Resource Centre (BRC) at Biopolis (IACUC no.: 080302). Researchers involved in this study passed a course on, "Responsible care and use of laboratory animals (RCULA)". Hypercholesterolemic mice (strain name: B6; 129S7-Ldlr tm1Her /J, LDLr / ) (Jackson Laboratory, USA) of 4 weeks old (n 9 per treatment group) were given either 0.026 mg ST, 1 mg (50 mg/ kg/day) T3, T3, T3 or their combinations dissolved in 50 M DMSO through oral gavage every 24 h. Control group was treated with DMSO. Their body mass was recorded daily. After 4 weeks, the mice were sacrificed for: (a) Lipid profiles. Blood was sampled were done immediately by cardiac puncture after euthanization by carbon dioxide (CO2) . The serum layer was used for quantitative analyses of total cholesterol, triglycerides and HDL levels, according to the manufacturer's protocol for CHOL, TRIGS and HDL kits (RANDOX Laboratories, UK). (b) Blood biomarker assay. In toxicity observation, serum biomarker measurements of the -T3-treated group were compared to the control group. The screened serum biomarkers were albumin (ALB), creatine (Crea), alanine aminotransferase (ALT), aspartate aminotransferase (AST), urea, and alkaline phophatase (ALP). All serum biomarker quantitative analyses were carried out according to the manufacturer's protocol (RAN-DOX Laboratories). (c) Serum level of T3 in mice. Forty 5-week-old hypercholesterolemic C57BL/6 mice were given a single-dose intraperitoneal (i.p.) injection of 1 mg (50 mg/kg/day) T3. Five mice were sacrificed at different time points (10 min, 30 min, 1 h, 3 h, 6 h, 24 h, 48 h and 72 h). Blood samples were collected through cardiac bleeding. To isolate the serum, blood samples were incubated at room temperature for 30 min, followed by centrifugation at 1900 xg, at 4 for 30 min. T3 concentration in serum was analyzed using the HPLC method above. (d) Single acute toxicity test. The maximum tolerated dose (MTD) was determined by increasing doses in different groups of mice until the highest dose without mortality was found. Briefly, 90 hypercholesterolemic C57BL/6 mice (10 in each group) received a single-dose i.p. injection of 1, 2, 4, 8, 12, 16, 20, 30 and 40 mg (50 − 2,000 mg/kg/day) T3 in 100 L injection volume. The weight and survival of mice were observed for 30 days, followed by euthanization by CO2 inhalation.
Clinical Study on Lipid Profile Improvement by T3
The clinical trial of T3 was performed using a double-blind placebo-controlled method. The trial protocol was performed in accordance with the Declaration of Helsinki 1964 (revised in '86/83/89/96/00/ 02/04), at Takara Clinic (Taisei Bldg, 9F, 2-3-2 Higashigotanda, Shinagawa-ku, Tokyo, Japan). The study protocol was approved by the Tokyo Medical and Dental University Ethics Committee and all patients gave written informed consent. The following ethical considerations were explained to the trial subjects: a) the human rights of subjects who enrolled in this study; b) the possible risks and benefits, adverse events and contribution to the medical field. Consequently, hypercholesterolemic subjects aged 25 − 55 (mean, 43 years old), with BMI 25 were selected. Exclusion criteria for pooled subjects were usage of drugs or other supplements, food allergy, possibility of pregnancy, or under treatment for chronic or lifestyle diseases. From the 40 initially recruited subjects, the top 50% (20 subjects) with regards to sd-LDL were enrolled in the study. These 20 subjects were randomly separated into 2 groups using StatLight. The T3 group (group A) consisted of 10 subjects (7 male, 3 female). The placebo group (group B) consisted of 9 subjects (6 male, 3 female) following the exclusion of 1 male subject. The final selected subjects had an age range of 49 to 54. During the 8-week treatment, subjects in group A were instructed to consume 4 caps of 30 mg T3 in 270 mg olive oil per day (twice per day, after breakfast and dinner, 2 caps per time). Subjects in group B were given similar instructions to consume 4 caps of 300 mg olive oil per day. Examinations parameters (body weight, height, waist measurement, hip measurement, systolic/diastolic pressures, body fat mass, muscle mass, edema, AST, ALT, ALP, bilirubin, urea nitrogen, creatinine, total cholesterol, triglyceride, HDL, LDL, 4 fractions of lipoprotein, cholesterol: 20 fractions of lipoproteins, triglyceride: 20 fractions of lipoproteins 22) ) were taken before and after the supplement intake.
Statistical Analysis
Statistical data wese analyzed using SPSS-Manager. Data are presented as the average SD. One-way analysis of variance (ANOVA) was used to compare differences between the experimental groups and the control/placebo group. A p value less than 0.05 was considered significant.
Results
Anti-Proliferation Effect of T3 in Human Hepatoma HepG2 Cells
Human hepatoma HepG2 cells were treated with T3 isomers for 24h at increasing dosage (low: 20, M medium: 40 M and high: 80 M). Our results showed that, except for -T3, the remaining T3 isomers significantly suppressed the proliferation of human hepatoma HepG2 cells at ≥ 20 M concentration (Fig. 1A) . The inhibition of cell proliferation was stronger for T3, particularly for T3, which showed a dose-dependent inhibition. Based on the 50% inhibition concentration, the order of the inhibitory effect was T3 T3 T3. Because experiments on lipidlowering are independent of HepG2 cell proliferation and cell apoptosis (Fig. 1B) , we used ≤ 20 M treatment dosage throughout this study.
T3 did not Affect mRNA Expression of Cholesterol and Triglycerides Biosynthesis genes in Human Liver Cell Line HepG2
To study the mechanism responsible for T3-induced lipid-lowering, the transcriptional changes of genes involved in cholesterol 6) and triglyceride 9) biosyntheses with or without T3 treatment were compared by RT-PCR. Treatment of HepG2 cells with LPDS, 25-HC, ST, T3 or their combined treat- Alpha-T3 Beta-T3 Gamma-T3 Delta-T3
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Cell Viability, % Tocotrienol Treatment, �M A B C ments did not result in transcriptional changes in SREBP1/2, HMGCR, apolipoprotein B48, apolipoprotein B100, apolipoprotein C, apolipoprotein E, and DGAT2 (Fig. 1C) . It was worth noting that combined treatment of T3 and -TP did not affect the mRNA of these genes.
T3 Downregulated Protein Expression of Cholesterol Biosynthesis genes in Human Hepatoma HepG2
Because SREBP1/2 and HMGCR are key regulators involved in endogeneous cholesterol biosynthesis, the possibility that T3-induced lipid-lowering may be attributed to the suppression of these genes was considered. Their protein expression in HepG2 cells treated with T3 was measured by Western blotting. As illustrated in Fig. 2A , culturing of HepG2 cells in LPDS induced the expressions of all three cholesterol biosynthesis genes, whereas treatment with either FBS or 25-HC repressed their protein expression compared to LPDS. Consistent with previous findings 23) , 5 uM ST treatment of HepG2 cells induced HMGCR and SREBP1/2 protein expression. In T3-treated HepG2 cells, a dose-dependent decrease in HMGCR protein was observed. which was associated the similar repression of its activators, SREBP1/2 (Fig. 2B) . These results indicated that T3 reduced cholesterol biosynthesis through the suppression of SREBP1/2 and HMGCR. The potency of their suppression was determined to be comparable.
Because TP was previously reported to attenuate the cholesterol-lowering capability of T3 24) , we therefore evaluated TP's ability to block T3-dependent HMGCR protein suppression. Our results indicated that 20 M TP did not inhibit the effect of T3-dependent HMGCR protein suppression ( Fig. 2A) . Protein expression of SREBP1/2 also did not support the role of TP as an antagonizing factor. In addition, a possible synergistic role between T3 and ST was also investigated. Unfortunately, combined T3 and ST did not result in enhanced suppression of either HMGCR or SREBP1/2.
T3 Upregulated LDL Receptor Expression in Human Liver Cell Line HepG2
LDLr binds to low-density lipoproteins, resulting in the increased clearance of circulating cholesterol. As illustrated in Fig. 2A , culturing of HepG2 cells in LPDS induced the protein expression of LDLr, whereas treatment with either FBS or 25-HC repressed it. Consistent with previous findings 25) , ST induced the biosynthesis of LDLr to draw cholesterol out of the blood circulation to compensate for the reduced levels of liver cholesterol. More interestingly, our results indicated that T3 enhanced the protein expression of LDLr more than ST for the removal of LDL from blood. When T3 was combined with TP or ST, no additional induction of LDLr was observed.
T3 Downregulates Protein Expression of Triglyceride Biosynthesis genes in Human Liver Cell Line HepG2
Because suppression of hepatic DGAT2 and APOB100 leads to the reduction of triglyceride synthesis and VLDL secretion from the liver, the possibility that T3 induced lipid-lowering attributable to the suppression of these genes was considered. VLDL is the metabolic precursor of LDL and is converted to LDL through the action of lipoprotein lipase, a triacylglycerol lipase that acts upon VLDL while it circulates in the bloodstream 26) . As illustrated in Fig. 2C , the protein expression of these two genes was repressed by T3 in a dose-dependent manner.
T3 Pharmacokinetics, Single Acute Toxicity and Serum Toxicity Biomarkers After One-Month T3 Supplementation
To evaluate the single acute toxicity of T3, T3 was injected intraperitoneally at 9 escalating doses to determine the maximum tolerated dose (MTD), which is defined as the dose at which none of the 10 mice die within a 30-day observation period and at least one of the mice dies at the next highest dose. As shown in Fig. 3A , MTD was determined to be 12 mg. For mice receiving 5 i.p. injections per week containing 1 mg T3 or DMSO blank for 4 weeks, there were no toxicological changes in the serum biomarkers examined (Fig. 3B) . In addition, the contents of T3 in vital organs (spleen, heart, lung, kidney, liver) were determined to mainly accumulated in the spleen and liver (Fig. 3C) .
We also studied the pharmacokinetic behavior of T3 in plasma after intra-peritoneal administration. Mice were injected with 1 mg T3 and blood was assayed for T3 concentration at different time points thereafter. As shown, the plasma T3 level decreased from 260 ppm to 50 ppm within 30 min after administration (Fig. 3D) / C57BL/6 mice before and after T3 treatment remained stable. (F) 1 mg/day T3 administered through oral gavage for 4 weeks reduced the total cholesterol, triglycerides and LDL levels by 25%, 19% and 51%, respectively in LDLr / C57BL/6 mice. The HDL level was not affected. It is worth noting that co-administration of 1 mg/day TP did not attenuate the anti-cholesterolemic property of T3. Also, 0.03 mg/day simvastatin did not result in cholesterol reduction because its activity in transgenic hypercholesterolemic mice is less obvious [28] [29] [30] [31] . " " denotes significant one-way analysis of variance (p value ≤ 0.05) when compared to untreated control group. Simvastatin+gamma delta T3 gamma delta T3+alpha TP ** ** ** ** ** ** ** ** ** **P<0.05 F mg/dL). Because ST is a first-line lipid-lowering drug in humans and can decrease LDL levels up to 50%, it was given through oral gavage for our in vivo study. The experiments were repeated three times.
Throughout the treatment period, mouse weights did not differ among groups (Fig. 3E) . As illustrated in Fig. 3F , serum cholesterol, triglycerides and LDL concentrations fell by 25%, 19% and 51%, respectively, after one-month T3 supplementation. The reduction in cholesterol and triglycerides resulting from T3 supplementation was more masked than from ST administration. Although ST is effective in humans 27) , its activity in hypercholesterolemic mice is less obvious [28] [29] [30] [31] as a result of LDLr mutation. It is worth noting that combined supplementation of T3 with either TP or ST did not improve the potency of T3.
Lipid Profile of Hypercholesterolemic Patients After 8-Week T3 Supplementation
The main characteristics (number of subjects, age, body weight, height, body mass index and initial cholesterol level) of the study population are outlined in Table 1 . There were no significant changes in these parameters between T3-treated and placebo subjects.
To evaluate whether T3 supplement reduced serum lipids, the current study evaluated changes in total serum cholesterol, triglycerides, LDL, HDL lipoproteins and their corresponding subfractions. After 8-week T3 treatment, the serum triglyceride level showed a statistically significant reduction ( 27.9%, p value 0.006), in stark contrast to the placebo group in which the triglyceride level showed an increasing trend (Fig. 4A) . Consistent with the lower triglyceride level, VLDL and chylomicron level in the treated group were also determined to be lower that with the placebo (Fig. 4B) . Unfortunately, the serum cholesterol level was not significantly altered in both treated and placebo groups (Fig. 4A) . Similarly, there were no changes in the 20 fractions of lipoproteins in both treated and placebo groups ( Table 1 Fig. 4 and  supplementary data) .
Discussion
The present study demonstrated that T3 is effective at lowering endogeneous cholesterol and triglyceride biosyntheses in HepG2 cells and hypercholesterolemic mice. Despite positive in vitro and in vivo results, our 8-week human trial using 120 mg/day T3 did not indicate any significant cholesterol reduction at the end of treatment. At the end of T3 supplementation, the serum triglyceride level showed statistically significant reduction of 27.9% compared to the baseline (p value 0.006). The concentrations of HDL and LDL remained stable during this period.
Lipid-Lowering Biopotency of T3 Depends on their Biological Half-Lives
Previous studies using various T3 formulations reached different conclusions regarding the most potent T3 isomer for reducing serum lipids. A doubleblind 4-wk study using 200 mg/day T3 resulted in 31%, 27% and 15% decrease in total cholesterol, LDL, and triglycerides, suggesting that T3 might be the most effective cholesterol-lowering isomer 12) . Note, however, that these changes in the T3 group may include a carry-over effect from earlier 4-week T3 supplementation and had no control group. In an other study 32) , researchers found that T3 was equally potent at suppressing the lipid profile. This was substantiated by Western blottings results 13) indicaing comparable suppression of HMGCR by T3. Using equimolar treatment dosages, our study consistently determined that the suppression level on SREBP2 was comparable between T3 (Fig. 2B) . Given that T3 itself affects the protein abundance of HMGCR through protein regulation and degradation 13) , its retention level (biological half-life) in cells is the central feature underlying its biopotency. To this end, it was previously determined that the unsaturated sidechain contributed most to the degradation of T3 to its water-soluble urinary metabolites. In particular, T3 was metabolized at a rate comparable to T3 33) . Taken together, it seems likely that T3 and T3 possess similar lipid-lowering activity.
Suppression of Triglycerides Biosynthesis by T3
To date, few papers published on T3 have discussed its triglyceride-lowering property 32, 34) . The lack of interest in this topic is possibly due to the unclear association between triglycerides and the risk of heart disease. Consequently, the T3 mechanism of action leading to the lowering of serum triglycerides remains unexplored. Recent studies have established that people with elevated triglycerides are indeed at increased cardiovascular risk, strongly associated with other risk factors, including low levels of HDL cholesterol, obesity, insulin resistance, diabetes, and a tendency toward excessive blood clotting 35) . In this study, we determined, for the first time, that T3 inhibited triglyceride biosynthesis through selective downregulation of DGAT2 and APOB100 protein expressions in a dose-dependent fashion (Fig. 2C) . This direct inhibition of DGAT2 and APOB100 proteins may be a more effective regulation by T3 than the signaling cascades for cholesterol biosynthesis genes. As this regulation is independent of sterol-sensing mechanisms, we observed a consistent lowering effect of triglycerides in both hypercholesterolemic mice and humans. Although the number of subjects investigated was insufficient for reasonable assurance of validity, the results were strengthened by the placebo group, which indicated an increasing trend of serum triglyceride level at the end of T3 supplementation. The cause of the increasing trend of triglycerides in the placebo group was not completely understood, although the most common metabolic basis seemed to be the altered diet during the trial, which included a holiday period (November 2008 − January 2009). Previously, Itoh 36) demonstrated that a high calorie diet composed of fat and simple carbohydrates had significant effects on the serum triglyceride level and body mass index (BMI) in the Japanese population. Consistent with their findings, the average daily calorie intake of subjects in the placebo group during the supplementation period was higher (2,200 kcal/day) than in the tocotrienol group (2,129 kcal/day). Consequently, this led to a concomitant increase in average body fat mass (22.6 5.1 kg to 23.5 4.9 kg), body fat rate (29.5 7.8% to 30.7 7.8 kg) and waist measurement (94. 6 6.1 cm to 95.3 8.0 cm) in the placebo group. These parameters were in stark contrast to the tocotri-enol group, which showed a decreasing trend at the end of T3 supplementation (supplementary data). Although these observations remain to be validated in a larger population, they will nevertheless aid in the development of future clinical trials on the triglyceride-lowering effect of T3.
Recently, eicosapentaenoic acid (EPA) purified from n-3 polyunsaturated fatty acids (PUFAs) has shown a proven triglyceride-lowering effect, and was approved by the Ministry of Health, Labour and Welfare of Japan as a treatment for hyperlipidemia and peripheral artery disease based on several large scale trials 37) . Surprisingly, the reduction of the serum triglyceride level in our T3-treatment group ( 27.9% at p value 0.006) was greater than that reported for EPA ( 10%) 38) . Other triglyceride-reducing agents such as niacin, which prevents the breakdown of fats and decreases VLDL secretion effectively, also lead to observable side effects 39) .
T3 Lowered Cholesterol, Triglyceride and LDL Levels in LDLr
/ Mice but not in Humans We hypothesized that the differential rates of post-absorptive T3 metabolism may be one of the major factors responsible for the discrepancies between in vitro and in vivo results and our human clinical trial findings. Although HepG2 cells express a variety of liver-specific metabolic functions 40) , they are not a suitable cell model to evaluate the lipid-lowering effects of T3 because the genes that encode for cytochrome P450 detoxification activity remain disappointingly low 41) , leading to the amplification of T3 effects not reproducible in human liver hepatocytes 42) . In other words, T3 accumulates in HepG2 cells as a result of lower biotransformation potential than primary hepatocytes. In human hepatocytes, T3 is metabolized efficiently by -oxidation followed by -oxidation of the side chain to make a water-soluble substrate for urine elimination 43) . Thus, the lipid-lowering effects observed based on HepG2 cells may not be reproducible in human patients unless a higher dose of T3 is administered.
T3 Lowered LDL Level in LDLr
/ Mice LDLr plays a critical role in the regulation of plasma LDL levels by mediating approximately two thirds of LDL clearance 44) . Loss of LDLr function leads to decreased LDL catabolism and elevated LDL levels 45) . Our study indicated that T3 lowered serum LDL after 4-week supplementation in LDLD / mice. Although the reduction in LDL caused by T3 could be partly accounted for by the suppression of hepatic triglyceride synthesis and VLDL secretion, it could also be due to the ability of apoE/apoB48 particles to bindi to chylomicron remnant receptors for endocytosis. Production of VLDL in mice involves apoB48, and 70% of apoB mRNA in the liver of adult mice encodes the apoB48 isomer 46) .
TP does not Affect the Lipid-Lowering Effects of T3
One published report postulated that the choles- ; however, no other researchers have been able to re-produce this finding or the mechanism involved in the attenuation effect. Our in vitro and in vivo results showed that high-dose TP (50% TP) co-treatment with T3 did not attenuate the suppression level of HMGCR-related genes and the in vivo serum lipid profile. Although a previous study explained that competition exists between T3 and TP for TP-transport protein (TTP), which primarily binds to TP, current findings support that oral T3 supplementation is transported to vital organs even in the absence of TTP 47) . There have been reports showing T3 presence in the skin, adipose, heart, lungs, skeletal muscle, brain, spinal cord and liver 47) . In some tissues (e.g. skin tissue serving as a storage organ for vitamin E), the level of T3 exceeded that of TP, indicating the presence of an efficient T3 transport system in vivo through blood plasma; therefore, the transportation of T3 may not entirely explain the negating impact of TP on the T3 lipid-lowering effect. More detailed experiments may be required to elucidate the antagonistic interaction between TP and T3 in lipid-lowering; however, it should be highlighted that TP did act as an antagonizing agent to T37) when TP prevented T3 degradation to longchain carboxychromanols 48) . The latter T3 metabolites serve as anti-inflammation and anticancer agents, and may contribute to the beneficial effects of T3.
Gamma-delta-T3
Conclusion
The results of the present study demonstrated that the lowering of serum triglycerides may be the primary health benefit caused by ingesting T3 in humans (Fig. 5) . Despite in vitro evidence suggesting the suppression of cholesterol pathway genes by T3, the absence of cholesterol reduction in our human trial, and others, may have resulted from the high rate of post-absorptive T3 degradation in the human liver. Thus, if hepatic T3 metabolism can be inhibited, leading to elevated T3 concentration, a T3 cholesterol-lowering effect can be demonstrated. This hypothesis remains plausible given that sesame seed lignan was previously shown to potently inhibit T3 metabolism ( 80%) in hepatocyte cells 33) . Finally, HepG2 liver cells may not be a suitable model to investigate the T3 cholesterol-lowering property due to its low cytochrome P450 activities associated with the degradation steps of T3.
